Candid Therapeutics is a clinical-stage biotechnology company developing novel T-cell engager (TCE) bispecific antibodies for autoimmune and inflammatory diseases. Founded in 2024 by Ken Song, the company combines assets from Vignette Bio and TRC 2004 to advance a pipeline of differentiated TCE therapies, with lead asset cizutamig in Phase 1 clinical studies.
Candid Therapeutics has been acquired
This company is no longer available on our private secondary market.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2024
Total Funding
$370M
1 rounds
Total raised $370M across 1 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series A
Date
September 9, 2024
Amount
$370M
Valuation
—
Lead Investors
Ken Song
Chairman, President & CEO
Tim Lu
Chief Medical Officer & Chief Scientific Officer
Arvind Kush
Chief Financial Officer & Chief Business Officer
Bernie Huyghe
Chief Technology Officer
Peter Wung
Senior Vice President, Clinical Development
David Luo
Senior Vice President, Clinical Operations
Angie You
Board Member
Dan Puckett
Board Member
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Gritstone bio
Immuno-oncology company developing cancer vaccines and cellular therapies
Abbvie
Multinational biopharmaceutical company with T-cell engager programs in autoimmune diseases
Amgen
Large biotechnology company with bispecific antibody programs
Eli Lilly
Multinational pharmaceutical company with immunology and bispecifics portfolio
Jounce Therapeutics
Immunotherapy company developing checkpoint inhibitors and T-cell engagers
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.